Alector is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, including Alzheimer's, ALS, and frontotemporal dementia. They are pioneering a new approach called "immuno-neurology," which seeks to harness the body's immune system to target brain diseases. Alector's pipeline includes promising therapeutic candidates that aim to slow or even halt the progression of these diseases. By leveraging cutting-edge immunology and human genetics, Alector is working toward breakthrough therapies that could have a profound impact on patients’ lives.